BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

April 25, 2025

Announcement no. 13

                                                                        

Managers’ transactions

In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.

1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameJens Due Olsen
2 Reason for the notification 
a)   Position/statusChair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 2,984,629
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameHenrik Juul
2 Reason for the notification 
a)   Position/statusVice Chair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
a)   Nature of the transactionSubscription of new shares in connection with private placement
b)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 746,157
c)   Aggregated informationn/a





d)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
e)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NamePeter Mørch Eriksen
2 Reason for the notification 
a)   Position/statusChief Executive Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 373,078
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameGry Husby Larsen
2 Reason for the notification 
a)   Position/statusChief Legal Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameNiels Høy Nielsen
2 Reason for the notification 
a)   Position/statusChief Financial Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on /investor-contact/.

For further information, please contact:

Hanne S. Foss, Head of Investor Relations, BioPorto, , C:

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit .

Attachment



EN
25/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto attends the Association for Diagnostics & Laboratory Medicine...

BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. July 28, 2025News Release BioPorto attends the Association for Diagnostics & Laboratory Medicine meeting, where NGAL and Acute Kidney Injury will be a key focus among participants. Laboratory medicine continues to focus on kidney diagnostics. BioPorto is pleased to announce its attendance and the general multiple NGAL and Acute Kidney Injury (AKI) focused elements of the Association for Diagnostics Medicine meeting, this year held in...

 PRESS RELEASE

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnost...

Påbegyndelse af kommercialisering af ProNephro AKI (NGAL) til diagnostisk brug i USA 27. juni, 2025Meddelelse nr. 18 Påbegyndelse af kommercialisering af ProNephro AKITM (NGAL) til diagnostisk brug i USA KØBENHAVN, DANMARK og BOSTON, MA, USA, 27. juni 2025 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) meddelte i dag, at de har påbegyndt kommercialisering i USA af ProNephro AKITM (NGAL) til klinisk anvendelse i risikostratificering af moderat til svær AKI for patienter i alderen 3 måneder til 21 år, ved at modtage den første købsordre på ProNephro AKITM (NGAL) til det amerik...

 PRESS RELEASE

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic...

Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US June 27, 2025Announcement no. 18 Initiation of commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US COPENHAGEN, DENMARK and BOSTON, MA, USA, June 27, 2025 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced the initiation of commercialization in the US of ProNephro AKITM (NGAL) for clinical use in risk stratification for moderate-to-severe AKI for patients aged 3 months to 21 years, by receiving the first purchase order of ProNephro AKITM (NGAL) for the US market...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 12. juni 2025Meddelelse nr. 17                                                                          Tildeling af Warrants København, Danmark, den 12. juni 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 3.250.000 warrants til Selskabets Extended Leadership Team. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,39 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i Selskabets...

 PRESS RELEASE

Grant of Warrants

Grant of Warrants 12 June 2025 Announcement no. 17                                                                          Grant of Warrants Copenhagen, Denmark, June 12, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 3,250,000 warrants to the Extended Leadership Team. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.39 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are issued in accord...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch